Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.75
20.31
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings Inc is a US-based company operating in industry. The company is headquartered in Dover, Delaware. The company went IPO on 2021-11-23. Cardio Diagnostics Holdings, Inc., formerly Mana Capital Acquisition Corp., is a biotechnology company that helps in cardiovascular disease prevention and early detection accessible. The firm is engaged in the development and commercialization of artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company enables prevention, early detection, and assists in the treatment of cardiovascular disease. The firm's Epi+Gen CHD is a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. Its Epi+Gen CHD test is categorized as a laboratory-developed test (LDT), which does not require premarket authorization or other Food and Drug Administration (FDA) clearance or approval. The company serves a range of patients, clinicians, hospitals/health systems, employers, and payors.
Cardio Diagnostics Holdings Inc is a US-based company operating in industry. The company is headquartered in Dover, Delaware. The company went IPO on 2021-11-23. Cardio Diagnostics Holdings, Inc., formerly Mana Capital Acquisition Corp., is a biotechnology company that helps in cardiovascular disease prevention and early detection accessible. The firm is engaged in the development and commercialization of artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company enables prevention, early detection, and assists in the treatment of cardiovascular disease. The firm's Epi+Gen CHD is a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. Its Epi+Gen CHD test is categorized as a laboratory-developed test (LDT), which does not require premarket authorization or other Food and Drug Administration (FDA) clearance or approval. The company serves a range of patients, clinicians, hospitals/health systems, employers, and payors.
